ConvaTec Responds to LCD Postponement in US
Why we think this is neutral
This RNS announcement is a general update on the postponement of Local Coverage Determinations (LCDs) for skin substitute products in the US. While this news is positive for ConvaTec's InnovaMatrix product, the announcement does not contain any mandatory news types such as contract news, order news, or financial figures. Therefore, the sentiment is assessed as neutral.
Key Points
- ConvaTec welcomes the postponement of LCDs for skin substitute products in the US
- This will allow continued access to ConvaTec's InnovaMatrix® product for Medicare patients
- ConvaTec is conducting randomised controlled trials for InnovaMatrix® in DFU and VLU, expected to report in 2026
Summary
ConvaTec welcomes the postponement by the Centers for Medicare & Medicaid Services (CMS) of the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the treatment of Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs). This means that Medicare patients will continue to benefit from access to ConvaTec's InnovaMatrix® product. ConvaTec remains committed to evidence-based medicine and is conducting randomised controlled trials for InnovaMatrix® in DFU and VLU, which are expected to report in 2026.